Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.
Funding
$28.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cell line development for biopharmaceutical production is a time-consuming and complex process, often resulting in low-yield and unstable cell lines. These inefficiencies increase development costs and delay the availability of new biologics.
Solution
Great Bay Bio offers AI-driven platforms, AlfaCell and AlfaMedX, designed to accelerate and optimize biopharmaceutical development. AlfaCell is a site-specific integration platform that streamlines cell line development to produce high-yield, stable cell lines in a reduced timeframe. AlfaMedX is an AI-enabled cell culture media development platform that optimizes cell culture conditions to maximize cell growth and productivity. Together, these platforms address key bottlenecks in biologics development, enabling faster and more efficient production of biopharmaceuticals.
Target Audience
The primary target audience includes biopharmaceutical companies, IVD manufacturers, and synthetic biology researchers seeking to improve the efficiency and speed of biologics development.
Features
- AlfaCell: Site-specific integration platform for rapid cell line development
- AlfaCell: Achieves high-yield and stable cell lines in approximately 1.5 months
- AlfaMedX: AI-enabled platform for cell culture media development
- AlfaOPA: AI-enabled no-screening cell culture media optimization platform
- Platforms applicable to biopharmaceutical, IVD, and synthetic biology applications